# Neoantigen-expanded Autologous Immune Cell Therapy

> **NCT05020119** · PHASE1 · UNKNOWN · sponsor: **Chang Gung Memorial Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Neoantigen-expanded cell therapy.

## Key facts

- **NCT ID:** NCT05020119
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-09
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05020119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05020119, "Neoantigen-expanded Autologous Immune Cell Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05020119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*